Biodesix Announces Presentations and Events at the CHEST 2025 Annual Meeting
Biodesix (Nasdaq: BDSX) announced presentations and events at the CHEST 2025 Annual Meeting, October 19–22 in Chicago. Preliminary CLARIFY study data from the first 1,000 enrolled patients will be presented in a sponsored Learning Theater on October 21 at 2:00 PM CDT by Michael Kammer, PhD.
The CLARIFY study is a real-world retrospective review designed to assess Nodify CDT and Nodify XL2 performance in up to 4,000 patients with ≥1-year follow-up. Multiple independent clinical presentations and a national analysis of pulmonary nodule healthcare resource utilization will also be presented. Biodesix leadership will staff booth #1012.
Biodesix (Nasdaq: BDSX) ha annunciato presentazioni ed eventi al CHEST 2025 Annual Meeting, dal 19 al 22 ottobre a Chicago. I dati preliminari dello studio CLARIFY dai primi 1.000 pazienti arruolati saranno presentati in una Learning Theater sponsorizzata il 21 ottobre alle ore 14:00 CDT da Michael Kammer, PhD.
Lo studio CLARIFY è una revisione retrospettiva del mondo reale progettata per valutare le prestazioni di Nodify CDT e Nodify XL2 in fino a 4.000 pazienti con follow-up di ≥1 anno. Verranno presentate anche molteplici presentazioni cliniche indipendenti e un’analisi nazionale sull’utilizzo delle risorse sanitarie relative ai noduli polmonari. La direzione di Biodesix gestirà lo stand #1012.
Biodesix ( Nasdaq: BDSX) anunció presentaciones y eventos en la CHEST 2025 Annual Meeting, del 19 al 22 de octubre en Chicago. Los datos preliminares del estudio CLARIFY de los primeros 1.000 pacientes inscritos se presentarán en una Learning Theater patrocinada el 21 de octubre a las 2:00 PM CDT por Michael Kammer, PhD.
El estudio CLARIFY es una revisión retrospectiva del mundo real diseñada para evaluar el rendimiento de Nodify CDT y Nodify XL2 en hasta 4.000 pacientes con un seguimiento de ≥1 año. También se presentarán múltiples presentaciones clínicas independientes y un análisis nacional sobre la utilización de recursos de atención sanitaria para nódulos pulmonares. La dirección de Biodesix atenderá en el stand #1012.
Biodesix (Nasdaq: BDSX)는 시카고에서 10월 19–22일 열리는 CHEST 2025 Annual Meeting에서 발표와 이벤트를 발표했습니다. 첫 1,000명 등록 환자에서 나온 CLARIFY 연구의 예비 데이터가 10월 21일 오후 2시 CDT에 Michael Kammer, PhD가 주관하는 스폰서 학습 극장에서 발표됩니다.
CLARIFY 연구는 실제 세계를 바탕으로 한 retrospective 연구로, 1년 이상 추적 관찰이 있는 최대 4,000명 환자에서 Nodify CDT와 Nodify XL2의 성능을 평가하도록 설계되었습니다. 독립적인 다수의 임상 발표와 폐 결절의 의료 자원 활용에 대한 전국적 분석도 발표될 예정입니다. Biodesix 경영진은 부스 #1012를 운영합니다.
Biodesix (Nasdaq : BDSX) a annoncé des présentations et des événements lors de la CHEST 2025 Annual Meeting, du 19 au 22 octobre à Chicago. Des données préliminaires de l’étude CLARIFY sur les premiers 1 000 patients inclus seront présentées dans une Learning Theater sponsorisée le 21 octobre à 14 h 00 CDT par Michael Kammer, PhD.
L’étude CLARIFY est une revue rétrospective du monde réel conçue pour évaluer la performance de Nodify CDT et Nodify XL2 chez jusqu’à 4 000 patients avec un suivi d’au moins 1 an. Plusieurs présentations cliniques indépendantes et une analyse nationale de l’utilisation des ressources de soins pour les nodules pulmonaires seront également présentées. La direction de Biodesix tiendra le stand n°1012.
Biodesix (Nasdaq: BDSX) kündigte Präsentationen und Veranstaltungen auf der CHEST 2025 Annual Meeting, vom 19. bis 22. Oktober in Chicago, an. Vorläufige CLARIFY-Studien-Daten von den ersten 1.000 eingeschriebenen Patienten werden am 21. Oktober um 14:00 Uhr CDT in einem gesponserten Learning Theater von Michael Kammer, PhD, vorgestellt.
Die CLARIFY-Studie ist eine realweltliche retrospektive Auswertung, die darauf abzielt, die Leistung von Nodify CDT und Nodify XL2 bei bis zu 4.000 Patienten mit mindestens einem Jahr Follow-up zu bewerten. Mehrere unabhängige klinische Präsentationen und eine nationale Analyse der Ressourcennutzung im Gesundheitswesen bei Lungenknötchen werden ebenfalls vorgestellt. Die Führungskräfte von Biodesix betreuen Stand Nr. 1012.
أعلنت Biodesix (ناسداك: BDSX) عن عروض وفعاليات في مؤتمر CHEST 2025 السنوي، من 19 إلى 22 أكتوبر في شيكاغو. ستُعرض بيانات مبكرة من دراسة CLARIFY من أول 1,000 مريض مُسجل في مسرح تعليمي برعاية يوم 21 أكتوبر في الساعة 2:00 بعد ظهرًا بتوقيت CDT بواسطة الدكتور مايكل كامير.
الدراسة CLARIFY هي مراجعة حقيقية من الواقع الطبي صُمِّمت لتقييم أداء Nodify CDT وNodify XL2 لدى حتى 4,000 مريض مع متابعة لا تقل عن سنة واحدة. كما ستُعرض عروض تقديمية إكلينيكية مستقلة متعددة وتحليل وطني لاستخدام موارد الرعاية الصحية لآفات الرئة. ستقوم قيادة Biodesix بإدارة الجناح #1012.
Biodesix（纳斯达克股票代码：BDSX）宣布在 CHEST 2025 Annual Meeting 的演讲和活动，10 月 19–22 日在芝加哥举行。对首批 1,000 名已入组患者的 CLARIFY 研究初步数据将于 10 月 21 日 CDT 下午 2:00 在由 Michael Kammer, PhD 主办的赞助学习剧场中进行披露。
CLARIFY 研究是一项真实世界的回顾性研究，旨在评估 Nodify CDT 和 Nodify XL2 在多达 4,000 名患者，随访不少于 1 年情况下的表现。还将展示多场独立的临床演讲以及对肺部结节医疗资源利用的全国性分析。Biodesix 的领导团队将值守摊位 #1012。
- None.
- None.
One year after launch of real-world CLARIFY study, preliminary data from the first 1,000 enrolled patients will be presented
LOUISVILLE, Colo., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announces educational events, abstracts, and activities at the 2025 CHEST Annual Meeting, October 19-22, in Chicago, Illinois.
Biodesix will be presenting data from an interim analysis of the CLARIFY study in a sponsored Learning Theater presentation.
Title: Driving to a New Standard of Care in Lung Nodule Management: Preliminary Results from the Nodify Lung Real-World CLARIFY Study
Presenter: Michael Kammer, PhD, Head of Radiomics at Biodesix
Location: Learning Theater 4
Date and Time: Biodesix Learning Theatre, October 21 at 2:00 pm CDT
Description: This presentation will review analysis from the first 1,000 patients enrolled in the CLARIFY study. The CLARIFY study began patient enrollment shortly after the 2024 CHEST Annual Meeting and is designed to confirm performance of the Nodify CDT® and Nodify XL2® tests in diverse patient subgroups through a retrospective chart review of up to 4,000 patients with at least 1-year follow-up since being tested in a real-world clinical setting. The study’s intent is to expand the extensive evidence characterizing the validation and utility of the Nodify Lung tests.
A national analysis of lung nodules receiving clinical work-up across diverse care settings will also be presented at the meeting, highlighting the need for more structured lung nodule management approaches to optimize efficiency of healthcare resource utilization and improve patient outcomes.
Title: Pulmonary Nodule-related Healthcare Resource Utilization After Diagnosis of Pulmonary Nodule in the United States
Presenting Author: Kimberly Le, PharmD, MS, MBA, Director of Health Economics Outcomes Research at Biodesix
Date and Time: Wednesday, October 22, 10:20 AM
It is important to note that there will be numerous independent presentations by healthcare professionals highlighting the clinical value of the Nodify Lung tests in their own real-world patient populations. Examples are below.
Title: Comparison of the Blood-based Nodify XL2 Test with PET/CT to Evaluate for Malignancy in Indeterminate Pulmonary Nodules in an Endemic Fungal Region
Presenting Author: Michael Torres Lizardi, MD
Date and Time: Sunday, October 19, 11:20 AM CDT
Title: Impact of the Nodify Lung Test Strategy in the Risk Stratification of Lung Nodules in Patients of a Pulmonary Practice in Miami
Presenting Author: Elizabeth Samper Perez
Date and Time: Wednesday, October 22, 10:20 AM CDT
Title: The Association of Lung Cancer Screening (LCS) and Proteomic Lung Nodule Testing in an Unrepresentative Minority Community (UMC) in Brooklyn, NY
Presenting Author: Juan Martinez Zegarra, MD
Date and Time: Wednesday, October 22, 10:20 AM CDT
Title: A Retrospective Analysis of Biodesix Biomarker to Assess Efficacy in Risk Stratification and Reduction of Invasive Surgical Procedures in Detected Solitary Pulmonary Nodules
Presenting Author: Kevin Huynh, DO
Date and Time: Wednesday, October 22, 10:20 AM CDT
In addition, Biodesix executive leaders and medical officers will be present at the Biodesix booth #1012 to discuss the future of biomarkers for lung nodule management and lung health diagnostics.
“It is an exciting time to be part of the lung diagnostics space, with biomarkers poised to transform and improve patient care,” said Scott Hutton, CEO at Biodesix. "With thousands of lung specialists coming together, the CHEST Annual Meeting offers a pivotal moment in lung diagnostics and in the fight against lung cancer. It’s great timing with Lung Cancer Awareness Month starting November 1st.”
About Biodesix:
Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.
Biodesix Contacts:
Media:
Natalie St. Denis, Director Corporate Communications, Biodesix
natalie.stdenis@biodesix.com
(720) 925-9285
Investors:
Chris Brinzey, Partner, ICR
chris.brinzey@icrhealthcare.com
(339) 970-2843
FAQ
When and where will Biodesix present preliminary CLARIFY study data at CHEST 2025 (BDSX)?
What does the CLARIFY study (BDSX) examine and how many patients will it include?
Who is presenting Biodesix’s Learning Theater on October 21 at CHEST 2025?
What other Biodesix sessions about Nodify Lung tests are scheduled at CHEST 2025 (BDSX)?
Will Biodesix executives be available at CHEST 2025 and where can investors find them (BDSX)?
What specific healthcare resource analysis will Biodesix present at CHEST 2025 (BDSX)?
